Back to top anchor

Can we attenuate inflammation in metabolic syndrome? A feasibility study

Year:
2021
Duration:
28 months
Approved budget:
$249,999.59
Researchers:
Associate Professor Anitra Carr
,
Dr Allamanda Faatoese
,
Dr Catherine Wall
,
Dr Emma Spencer
,
Dr Jonathan Williman
Health issue:
Obesity
Proposal type:
Feasibility Study
Lay summary
Metabolic syndrome (MetS) is an increasingly prevalent condition that comprises a group of risk factors, including abdominal obesity, insulin resistance (pre-diabetes), hypertension and hyperlipidemia, which together significantly increase the risk of type-2 diabetes and cardiovascular disease (CVD). Chronic low-grade inflammation contributes to the insulin resistance and vascular dysfunction observed in MetS. Targeting these inflammatory pathways in MetS may help attenuate progression to the more severe cardiometabolic diseases. Vitamin C is a potent antioxidant with anti-inflammatory properties and is depleted in people with MetS. Therefore, we plan to carry out a study to assess the feasibility of a randomised controlled trial comprising vitamin C supplementation of people with MetS to determine effects on inflammation and other objective and subjective health measures. A diagnosis of MetS provides a window of opportunity to work with those diagnosed to make healthful lifestyle changes to potentially slow or even reverse progression to diabetes and/or CVD.